Litcius/Paper detail

Recurrent neurosurgical site infection by extensively drug-resistant <i>P. aeruginosa</i> treated with cefiderocol: a case report and literature review

Davide Fiore Bavaro, Federica Romanelli, Stefania Stolfa, Alessandra Belati, Lucia Diella, Luigi Ronga, C Fico, Laura Monno, Adriana Mosca, Annalisa Saracino

2020Infectious Diseases23 citationsDOI

Abstract

Introduction Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections.Case presentation We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision.Conclusions Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.

Topics & Concepts

MedicineCephalosporinPseudomonas aeruginosaAntimicrobialPneumoniaAntibioticsUrinary systemIntensive care medicineAntibiotic resistanceMicrobiologyBacteriaInternal medicineBiologyGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyBacterial Infections and Vaccines